Role of CCK1 receptor in metabolic benefits of intestinal enteropeptidase inhibition in mice
Fig 2
Effect of FOY-251 and/or loxiglumide on gastric emptying and food intake in fasted DIO mice.
(A) Blood acetaminophen appearance following treatment with 100 mg/kg oral FOY-251, 30 mg/kg loxiglumide, or their combination (N = 7-8/group). 20 μg SC exendin-4 was used as a positive control to validate the experimental model (N = 5). All animals received oral gavage or subcutaneous injection at the following timepoints: oral vehicle (20%HP-β-CD) or loxiglumide (t = −40 min), oral vehicle (5%HPMC) or FOY-251 (t = −30 min), subcutaneous PBS or exendin-4 (t = −20 min), followed by oral acetaminophen (100 mg/kg) at t = 0 min. *p < 0.05 vs vehicle control group. (B) Integrated blood acetaminophen for data shown in panel (A). (C) 4-hour food intake in DIO mice administered oral vehicle or loxiglumide (t = −60 min), followed by oral vehicle, FOY-251 or Rimonabant at t = −30 min. Food consumption during the dark phase was measured over 4-hours starting at t = 0 min (N = 8/group). Values are expressed as mean ± SEM; *p < 0.05 for the indicated comparisons.